MedTrace Logo

A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.

NCT07392736 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2026-02-06

No results posted yet for this study

Summary

This trial is an open, non-randomized, phase I/IIa clinical trial, which will evaluate the preliminary effectiveness and safety of AL8326 tablets in patients with advanced solid tumors

Conditions

Interventions

DRUG

AL8326 tablets

Tablet: 10mg/tablet; administered orally once daily

DRUG

Toripalimab

240mg Injection solution：21-Day cycles

Sponsors & Collaborators

  • Advenchen Laboratories, LLC

    lead INDUSTRY

Principal Investigators

  • Jing wang · Hunan Cancer Hospital

  • LingYIng Wu · The Cancer Hospital of the Chinese Academy of Medical Sciences

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-26
Primary Completion
2029-11-07
Completion
2029-11-07

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07392736 on ClinicalTrials.gov